Navigation Links
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
Date:1/29/2012

vely work with the European Commission and the EMA to find the best process going forward, not only for Glybera but also for further advanced therapies on their way to patients," said Jörn Aldag, CEO of AMT. "While gaining clarity for the process involving Glybera, we will continue to implement our revised business strategy revealed following the last CHMP decision. This involves moving forward in partnering discussions for several of our gene therapy products, including hemophilia B and GDNF."

AMT's current business plan, organizational structure and financing have been developed on the basis of the current CHMP opinion for Glybera's non-approval. It involved a reduction of its workforce by about 50%. In the event that Glybera could be commercialized in Europe, the Company will evaluate how the opportunity arising from passing this important milestone could be realized most efficiently.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life-threatening clinical complication of LPLD. Glybera has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. In addition to Glybera, AMT has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute interm
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
2. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
3. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
4. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
5. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
6. MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support
7. Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging
8. Quest Diagnostics Launches Simplexa™ Dengue Test in Brazil, First Commercial Molecular Test Approved for Nations Public and Private Health Testing
9. Roche Diagnostics, Cedars-Sinai Medical Center Enter Strategic Alliance for Center to Operate as a Roche Molecular Center of Excellence
10. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
11. GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
(Date:5/21/2015)... Research and Markets ... of the "Arthroscopy Devices Markets Worldwide" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this report ... market for Arthroscopy Devices. The report discusses ... market for these products. , ,Product - ...
(Date:5/21/2015)... , 21. Mai 2015 ... ), ein Unternehmen für Arzneimittel im ... Entwicklung und Vermarktung von Locilex® (Pexiganan-Creme ... heute eine wissenschaftliche Posterpräsentation an, welche ... Unternehmens vorstellt, OneStep-1 und OneStep-2, in ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
(Date:5/23/2015)... Manufacturers are now required to produce water ... 8.2. Experts in the field agree that the regulation is ... HSPF score is what miles per gallon is to your ... Although the minimum HSPF score has been raised to 8.2, ... score north of 12. Indeed, the regulation was welcomed by ...
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on ... Maryland legislature but which has not been signed to date ... HB 449 with overwhelming bipartisan support on April 10, ... law. This bill ensures that fracking is prohibited in Maryland ... danger of fracking to our water supplies and the air ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan Valley Medical ... 29, 2015 at 11 a.m., followed by a community celebration ... set to officially open on June 1, 2015, is located ... “The opening of Mountain Point Medical Center is an exciting ... Kent Loosle, CEO of Mountain Point Medical Center. “Mountain Point ...
(Date:5/22/2015)... 2015 Omar Ahmad Barrada, a junior ... in the 2015 Congress of Future Medical Leaders in ... gathering of “America’s highest achieving high school students.” , ... set new goals and learn better study habits,” said ... during which we can ask the surgeons questions.” , ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Family, friends, ... Hospital’s world-renowned surgical oncologist, Dr. LaSalle D. Leffall, on ... The luncheon began after Grand Rounds in the hospital’s ... waited anxiously outside the auditorium, trying to keep the ... but if he sees me, he’ll know something is ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... Provides Update on Oncology Pipeline Progress, SAN DIEGO, ... announced financial results for the three and nine,months ended ... 30,2007, the Company posted revenues of $7.6 million and ... ended September 30, 2007, revenues were $27.1,million and the ...
... Human Vaccine Against West Nile Virus Today; ... Disease Endemic in the United States, ... of sanofi-aventis Group, announced today that it has,signed an exclusive ... of a West Nile vaccine to help fight against,this serious, ...
... urinary levels of certain molecules might have the potential ... ailment caused by the autoimmune disease lupus, UT Southwestern ... a quartet of molecules may have potential diagnostic significance, ... senior author of a study available online at the ...
... CRME TSX: COM, VANCOUVER, Nov. 12 /PRNewswire-FirstCall/ - ... that it will report 2007 third,quarter financial results on ... a teleconference call and webcast at 4:30pm Eastern Time,(1:30pm ... To access the conference call, please dial 416-340-8010 ...
... Nov. 12 ,Seeking to expand Indo-U.S. healthcare ... Healthy India launched its inaugural,executive mission to ... from the,most prominent players in healthcare, including: ... Avesthagen, Excel Life Sciences,Cognizant, Stryker, BD, Yes ...
... plaguing inner-city youth at epidemic rates, the report of ... Journal of the American College of Surgeons illustrated a ... study showed that Caught in the Crossfire, a hospital-based ... system among youth aged 12 to 20. Additionally, ...
Cached Medicine News:Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 2Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 3Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 4Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 5Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 6Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 7Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 8Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:Researchers investigate ways to detect lupus-associated kidney disease 2Health News:Cardiome To Release Third Quarter Results 2Health News:Cardiome To Release Third Quarter Results 3Health News:USIBC Launches Healthcare Mission to India 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 3
... UC-Plus Solution knee is the state of ... replacement. Geometry of the articular surfaces does ... anatomical variations, and achieves a wide area ... components. Large, uninterrupted pockets of cement create ...
... The TC-PLUS Solution tricompartmental total knee ... with knee arthroplasty. State-of-the-art design and manufacturing ... achieve optimum biomechanical function as well as ... polyethylene tibial insert to keep wear to ...
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The modern design allows extremely sparing resections. The components exhibit an anatomical geometry t...
... is a long term, quality solution based ... both posterior stabilized and anatomically correct cruciate ... the flexibility needed to address patients' needs. ... identification keeps the user in mind and ...
Medicine Products: